The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis
Authors
Keywords
-
Journal
Scientific Reports
Volume 8, Issue 1, Pages -
Publisher
Springer Nature America, Inc
Online
2018-08-31
DOI
10.1038/s41598-018-30780-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis
- (2018) Francesco Passiglia et al. CURRENT CANCER DRUG TARGETS
- Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR -Mutated NSCLC
- (2018) Anna Buder et al. Journal of Thoracic Oncology
- Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms
- (2017) Kenichi Suda et al. Expert Review of Anticancer Therapy
- Development and Clinical Utility of a Blood-Based Test Service for the Rapid Identification of Actionable Mutations in Non–Small Cell Lung Carcinoma
- (2017) Hestia Mellert et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib
- (2017) Suzanne Jenkins et al. Journal of Thoracic Oncology
- Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer
- (2017) Suzanne Jenkins et al. Journal of Thoracic Oncology
- Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer
- (2017) Norimitsu Kasahara et al. LUNG CANCER
- Optimal method for quantitative detection of plasma EGFR T790M mutation using droplet digital PCR system
- (2017) Ken Suzawa et al. ONCOLOGY REPORTS
- Conventional real-time PCR-based detection of T790M using tumor tissue or blood in patients with EGFR TKI-resistant NSCLC
- (2017) Ya-Lan Wu et al. OncoTargets and Therapy
- Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) S. Novello et al. ANNALS OF ONCOLOGY
- Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA
- (2016) J. C. Thompson et al. CLINICAL CANCER RESEARCH
- Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)
- (2016) C. Karlovich et al. CLINICAL CANCER RESEARCH
- Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
- (2016) Geoffrey R. Oxnard et al. JOURNAL OF CLINICAL ONCOLOGY
- A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma
- (2016) Karen L. Reckamp et al. Journal of Thoracic Oncology
- Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors
- (2016) Y. Seki et al. ONCOLOGIST
- Detection of the T790M mutation of EGFR in plasma of advanced non–small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study)
- (2016) Takayuki Takahama et al. Oncotarget
- A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance
- (2016) Wenxian Wang et al. Cancer Medicine
- Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung Cancer
- (2016) Adrian G. Sacher et al. JAMA Oncology
- Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses
- (2015) T. K. Sundaresan et al. CLINICAL CANCER RESEARCH
- Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients
- (2015) C. P. Paweletz et al. CLINICAL CANCER RESEARCH
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
- (2015) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291
- (2015) Kenneth S. Thress et al. LUNG CANCER
- Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples
- (2015) Hidenobu Ishii et al. Oncotarget
- Circulating Tumor DNA Is Effective for the Detection of EGFR Mutation in Non-Small Cell Lung Cancer: A Meta-analysis
- (2014) M. Qiu et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors
- (2014) Christian Rolfo et al. CANCER TREATMENT REVIEWS
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
- (2010) David Moher et al. International Journal of Surgery
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now